A Trial to Evaluate the Effectiveness, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

Overview

About this study

The primary purpose of this study is to demonstrate the effectiveness of 1 or 2 dose levels of HZN-825 versus placebo in subjects with diffuse cutaneous Cutaneous System Sclerosis (SSc), as determined by a comparison of change in forced vital capacity (FVC) % predicted after 52 weeks of treatment.

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Written informed consent.
  • Male or female between the ages of 18 and 75 years, inclusive, at Screening.
  • Meets the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for SSc with a total score of ≥ 9 (Van den Hoogen et al., 2013).
  • Classified as having skin involvement proximal to the elbow and knee (diffuse cutaneous SSc subset by LeRoy and Medsger, 2001).
  • At the time of enrollment, less than 36 months since the onset of the first SSc manifestation, other than Raynaud's phenomenon.
  • Based on data available through medical history and/or medical records, the subject should have at least 1 of the following:
    • disease duration ≤ 18 months;
    • increase ≥ 3 in mRSS units compared with the last visit within the previous 1 month to 6 months;
    • involvement of 1 new body area with ≥ 2 mRSS units or 2 new body areas with ≥1 mRSS unit;
    • documentation of worsening skin thickening for subjects who did not have mRSS performed during the previous visit;
    • presence of tendon friction rub at Screening.
  • Presence of at least 1 of the following features of elevated acute phase reactants at Screening:
    • high-sensitivity C-reactive protein (hsCRP) ≥0.6 mg/dL (≥ 6 mg/L);
    • erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr;
    • platelet count ≥ 330 × 10^9/L (330,000/μL).
  • Skin thickening from SSc in the forearm suitable for repeat biopsy.
  • mRSS units ≥ 15 at Screening.
  • FVC ≥ 45% predicted at Screening, as determined by spirometry.
  • Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.

Exclusion Criteria:

  • Positive for anti-centromere antibodies.
  • Diagnosed with sine scleroderma or limited cutaneous SSc.
  • Diagnosed with other autoimmune connective tissue diseases, except for fibromyalgia, scleroderma-associated myopathy and secondary Sjogren's syndrome.
  • Scleroderma renal crisis diagnosed within 6 months of the Screening Visit.
  • Any of the following cardiovascular diseases:
    • uncontrolled, severe hypertension (≥ 160/100 mmHg) or persistent low blood pressure (systolic blood pressure < 90 mmHg) within 6 months of Screening,
    •  myocardial infarction within 6 months of Screening,
    •  unstable cardiac angina within 6 months of Screening.
  • DLCO < 40% predicted (corrected for hemoglobin). If severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure is of clinical concern for any subject, consider using a DLCO up to 6 months before the Screening Visit.
  • Pulmonary arterial hypertension (PAH) by right heart catheterization requiring treatment with more than 1 oral PAH-approved therapy or any parenteral therapy. Treatment is allowed for erectile dysfunction and/or Raynaud's phenomenon/digital ulcers.
  • Corticosteroid use for conditions other than SSc within 4 weeks prior to Screening (topical steroids for dermatological conditions and inhaled/intranasal/intra-articular steroids are allowed).
  • Use of any other non-steroid immunosuppressive agent, small biologic molecule, cytotoxic or anti-fibrotic drug within 4 weeks of Screening, including cyclophosphamide, azathioprine (Imuran®) or other immunosuppressive or cytotoxic medication. Exceptions include mycophenolate mofetil (CellCept®), mycophenolic acid (Myfortic®), methotrexate and low-dose prednisone, as follows: use of CellCept ≤ 3 g/day, Myfortic ≤ 2.14 g/day, methotrexate ≤ 15 mg/week and prednisone ≤ 10 mg/day (or equivalent dosing of glucocorticoids) is allowed. Subjects taking CellCept, Myfortic or methotrexate must have been doing so for ≥ 6 months and the dose must have been stable for ≥ 16 weeks prior to the Day 1 Visit. Prednisone must have been at a stable dose for ≥ 8 weeks prior to the Day 1 Visit. It is acceptable to be on background low-dose prednisone and anti-malarial drug along with CellCept, Myfortic or methotrexate. Rituximab must not have been used within 6 months of the Day 1 Visit.
  • Known active bacterial, viral, fungal, mycobacterial or other infection, including tuberculosis or atypical mycobacterial disease (fungal infections of nail beds are allowed).
  • Use of a United States Food and Drug Administration-approved agent for SSc or an investigational agent for any condition within 90 days or 5 half-lives, whichever is longer, prior to Screening or anticipated use during the course of the trial. 12. Malignant condition in the past 5 years (except successfully treated basal/squamous cell carcinoma of the skin or cervical cancer in situ).
  •  Women of childbearing potential or male subjects not agreeing to use highly effective method(s) of birth control throughout the trial and for 1 month after last dose of trial drug. Male subjects must refrain from sperm donation and females from egg/ova donation for this same time period.
  • Pregnant or lactating women.
  • Current drug or alcohol abuse or history of either within the previous 2 years, in the opinion of the Investigator or as reported by the subject.
  • Previous enrollment in this trial or participation in a prior HZN-825 or SAR100842 clinical trial.
  • Known history of positive test for human immunodeficiency virus.
  • Active hepatitis (hepatitis B: positive hepatitis B surface antigen and positive anti-hepatitis B core antibody [anti-HBcAb] and negative hepatitis B surface antibody [HBsAb] or positive for HBcAb with a positive test for HBsAb and with presence of hepatitis B virus DNA at Screening; hepatitis C: positive anti-hepatitis C virus [anti-HCV] and positive RNA HCV).
  • Current alcoholic liver disease, primary biliary cirrhosis or primary sclerosing cholangitis.
  • Previous organ transplant (including allogeneic and autologous marrow transplant).
  • International normalized ratio > 2, prolonged prothrombin time > 1.5 × the upper limit of normal (ULN) or partial thromboplastin time > 1.5 × ULN at Screening.
  • Alanine aminotransferase or aspartate aminotransferase > 2 × ULN.
  • Estimated glomerular filtration rate < 30 mL/min/1.73 m^2 at Screening.
  • Total bilirubin > 2 × ULN. Subjects with documented diagnosis of Gilbert's syndrome may be enrolled if their total bilirubin is ≤ 3.0 mg/dL.
  • Any other condition that, in the opinion of the Investigator, would preclude enrollment in the trial.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ashima Makol, M.B.B.S.

Open for enrollment

Contact information:

Kathleen McCarthy-Fruin M.S.

(507) 284-4797

McCarthy-Fruin.Kathleen@mayo.edu

More information

Publications

Publications are currently not available
.

Mayo Clinic Footer